Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID MeetingApril 29, 2013
Durata presented data from a Phase 1 study showing its lead product candidate, dalbavancin, under investigation for the treatment of susceptible gram positive bacterial infections including MRSA, is well tolerated in healthy subjects.
Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical TrialsApril 25, 2013
The financing will support advancement of Esperion’s novel lead product candidate, ETC-1002, in multiple ongoing and planned Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic disorders.
Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement $20M Committed PIPE Financing to Close with MergerApril 23, 2013
The merger is expected to create a NASDAQ-listed company focused on the development of novel therapeutics for patients with acute and chronic decompensated liver disease. Upon closing, the company will be named “Ocera Therapeutics, Inc.”